Medicines

VEN130: Osteoporosis

Approximately 20% of American women older than age 50 have the thinning of bone tissue and loss of bone mineral density that are the hallmarks of osteoporosis. The leading cause of osteoporosis is age-related changes in hormone levels that alter the sensitive dynamic between the bone cells known as osteoblasts, which continually build new bone in the body, and osteoclasts, which continually resorb bone. While most existing osteoporosis treatments target osteoclast activity, an alternative approach would be to simultaneously promote osteoblast activity to increase the formation of healthy new bone mass.

Preclinical and pilot clinical studies have suggested that VEN130 may exert a favorable effect on the osteoblast/osteoclast balance, and Ventria Bioscience is currently investigating it as a therapeutic candidate